Foamix to Present Corporate Overview at the 3rd Annual Dermatology Summit Meeting
January 04, 2016 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), a clinical stage specialty pharmaceutical company focused on developing and...
Foamix Announces Positive Top-Line Results From Phase II Study for FDX104 (Doxycycline Foam) in the Prevention of Acneiform Rash Associated With Targeted Antibody Treatments for Colon and Head and Neck Cancers
December 03, 2015 07:00 ET
|
Foamix, Ltd.
FDX104 prevented the development of moderate-to-severe antibody-induced rash in the majority of cases.
FDX104 appears safe and was well-tolerated.
REHOVOT, Israel and BRIDGEWATER, N.J.,...
Foamix to Host Conference Call & Webcast to Discuss Topline Results From Phase 2 Study of FDX-104 in Acneiform Rash Associated With Targeted Antibody Treatments for Colon and Head and Neck Cancers
December 02, 2015 16:01 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Dec. 2, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing...
Foamix to Present Corporate Overview at the Oppenheimer 26th Annual Healthcare Conference
December 01, 2015 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Dec. 1, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused...
Foamix to Present Corporate Overview at Jefferies Autumn 2015 Global Healthcare Conference in London
November 11, 2015 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company...
Foamix Reports Third Quarter 2015 Financial Results and Provides Business Update
November 11, 2015 07:00 ET
|
Foamix, Ltd.
REHOVOT, Israel, Nov. 11, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and...
Foamix Pharmaceuticals Third Quarter 2015 Conference Call and Webcast Scheduled for Wednesday, November 11
October 27, 2015 13:00 ET
|
Foamix, Ltd.
REHOVOT, Israel, and BRIDGEWATER, N.J., Oct. 27, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company...
Foamix Announces Enrollment of First Patient in Phase 2 Clinical Trial of FMX103 in Papulopustular Rosacea
October 20, 2015 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 20, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company...
Foamix Reports Second Quarter 2015 Financial Results and Provides Business Update
August 19, 2015 16:01 ET
|
Foamix, Ltd.
REHOVOT, Israel, Aug. 19, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and...
Foamix Pharmaceuticals Second Quarter 2015 Conference Call & Webcast Scheduled for Thursday, August 20
August 13, 2015 08:00 ET
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company...